I have a close family member who had Covid, and experienced

New Post Public Reply Private Reply Replies (4) Message Board
CYDY_Invest
2,443
I have a close family member who had Covid, and experienced Long Haul symptoms. She recently was tested and treated with Bruce Patterson’s company IncellDx for Covid Long Haul, and she thinks it was a complete rip off. She’s intelligent, open minded, and was willing to give it a shot. After her initial sign up, some challenges up front were lack of/poor communication of where to get blood drawn. Finally someone from the company got back to her after they were contacted numerous times. (BTW, I think IncellDx’s website is not very organized and just doesn’t look good.)

Her Covid Long Haul panel tested abnormally high positive for 10 cytokine/chemokines and also positive for the Long Haul index algorithm. Her 2 current physicians (who are very smart well-trained doctors) weren’t comfortable prescribing the repurposed drugs that were recommended (Statins, Steroids, Ivermectin, etc). So, the only way to get the drugs prescribed were from 2 physicians that were in her area that IncellDx recommended (One was about to relocate). She went with the available doctor, and had to pay $750 (out of pocket) for treatment and follow up. She paid the $750 and took the recommended drugs for the duration suggested.

This doctor she used (referred by IncellDX) was completely incompetent. My family member asked her about the purpose of different drugs and for what elevated cytokines etc, and the doctor said absolutely nothing, didn’t have a clue about immunology. My family member mentioned she felt Ivermectin was giving her an upset stomach, and if it was okay to stop Ivermectin. The doctor had absolutely no opinion. Other questions she had the doctor didn’t say anything – was totally useless. Obviously, this was very upsetting to my family member.

She decided to stick with the recommended full treatment of drugs and duration and to see what happens with the follow up lab test. Will this help her abnormally high cytokines and Long Haul index score? The answer was no, not at all. We recently got the follow up test and it showed abnormally high positives now for 11 cytokine/chemokines and still positive for the LongHaul index score, so it actually got a little worse.

And symptomatically for her, nothing improved.

I know this is one patient's story, but I share this to mention that Patterson’s testing methodology and use of repurposed drugs is not proven. (13D group thinks Patterson has the holy grail answer to Covid Long Haul). There are no placebo control double blinded trials showing this works. I’m not trying to be a basher, just that this is unproven. I recently talked to my family member, and she repeated saying, “this was a total rip off.” She is pretty angry, and still suffering.

Also the lab tests IncellDx uses are not FDA reviewed or approved. They are called “Laboratory Developed Tests” (in the past LDTs were known as “Homebrew tests”), and they don’t carry the same weight of clinical evidence that FDA approved tests do. It's good to keep this in perspective.

I went over that IncellDx lab report from my family member which says below the data just to quote, “The LDT (laboratory developed test) tests comprising the panel has not been reviewed by the US FDA.”

I went to the FDA website to cite a reference to LDTs if anyone is interested:
https://www.fda.gov/media/102367/download

“Many stakeholders, in addition to FDA, have indicated that there is a public health need for greater oversight of LDTs.” (in the conclusion of the link)

The 13d group it seems has put Patterson on a pedestal with hero worship. Almost cult like praise, the group built around 1 person. They think his TedTalk caused the $10 sp spike. That’s crazy talk, such a reach. He’s not famous. Also, why the dump then? This was Covid stock season pump and dump. 13d claims they’ll get a fast enrollment for Long Haul Phase 3. Current management had a very fast Covid Long Haul Phase 2 fill up with Dr. Norman Gaylis (on the SAB who is extremely qualified, and not looking to take over the company). They had a record setting NASH Phase 2 enrollment. I expect current management to have a fast enrollment of Long Haul Phase 3, under Dr. Recknor.

13d brings nothing new, only a ton of risk. Let’s not give them the keys to the car. They say they have funding lined up and don’t talk to Big Pharma, however we have no way of knowing what they really are able to, and willing to do. Again, just to keep things in perspective, Patterson is not the only CCR5 expert. Do a PubMed search on CCR5 and you will get over 10,000 articles from scientists all over the world discussing CCR5. Also, there are now numerous Long Haul clinics and institutions researching this disease (not just IncellDx).

Many of us investors are not scientists and may not have technical expertise, however we can still make a good judgement about the future of our company.

I like our current management team together with the 8 highly qualified Scientific Board of Advisors. I like the progress and direction, and I know what to expect from them. I have a lot of shares and it’s in my financial interest to support them.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Baystate Health Expands: A New Chapter with Mercy

Updated Category News Views 96

Baystate Health Moves Forward with Strategic Integration Well, here's a tale that's as much about legacy as it is about progress. Baystate Health has brought Baystate Mercy Hospital into its fold, blending history with future prospects. This integration, folks, isn't just a merger—it's a downright overhaul of how healthcare operates in Western Massachusetts. We’re...

Continue Reading
CJ BIO's Bold Steps for Sustainable Animal Nutrition

Updated Category News Views 343

Breaking New Ground in Animal Nutrition Picture this: industry big wigs and farmers alike, all rubbing elbows at EuroTier 2026, the grand meeting ground for animal nutrition's future. This is where CJ BIO is flexing its muscles, not by just tossing ingredients into the mix, but by revolutionizing them under the banner "Feed Intelligence for Sustainable Performance." Now,...

Continue Reading
Bass Angler Matt Robertson Reels in Record $1.25M Prize

Updated Category News Views 312

A New Era for Bass Fishing Payouts Who would have thought we'd see the day when bass fishing turned out to be as lucrative as a Wall Street handshake? But here we are, with Matt Robertson hauling in a whopping $1.25 million prize at World Bass Enterprises' first "The Champions" Tournament. We're not talking chump change here—this is the real deal in a sport often...

Continue Reading
Navigating Underinsured Motorist Coverage Woes

Updated Category News Views 141

When the Rubber Hits the Road: Coverage Gaps Ever been in a fender bender and found out the other driver’s insurance barely covers a dent, let alone a serious crash? Believe me, it's no picnic. Chuck Clark from HelloNation digs into this with a deep dive on underinsured motorist coverage, or UIM for short. It's an eye-opener—especially if you're assuming your auto...

Continue Reading
Yangtze River Culture Festival Spotlights Integration, Tradition

Updated Category News Views 262

A Celebration of Culture and Integration Here's an event that flips the script on the typical festival circuit: the 2026 Yangtze River Culture Festival. It's as much about heritage as it is about economics, dovetailing culture with tourism in a way that makes wallets a little fatter and souls a little richer. Kicking off in Yonglian Village, Zhangjiagang, this festival...

Continue Reading
Abbott's SonicForce Impresses in Crucial Clinical Trial

Updated Category News Views 43

Breaking Through Cardiac Barriers Never thought I'd see the day when we're literally sending shockwaves through the heart, but here we are. Abbott's makin' waves, quite literally, with its SonicForce™ Coronary Intravascular Lithotripsy (IVL) System. They’ve just dropped some promising 30-day outcomes from the TECTONIC study, which has grabbed the spotlight at the...

Continue Reading
Ensuring Flooring Stability: Acclimation's Key Role

Updated Category News Views 168

Dive into the World of Flooring Acclimation You ever hear about flooring acclimation? Sounds as riveting as watching paint dry, right? But Austin J. Messina from Salem, New Hampshire, is here to tell us it's the secret to flooring that doesn't buckle under pressure—literally. Messina's insights, splashed across the pages of HelloNation, delve deep into the nitty-gritty...

Continue Reading
UPM-Kymmene Finalizes Demerger: WISA Group to Nasdaq

Updated Category News Views 94

UPM-Kymmene Shakes Things Up Here's the meat and potatoes: UPM-Kymmene Corporation is going through a big change. They've decided to cut a part of themselves off and send it out into the world. This partial demerger has been registered, and now WISA Group Plc is stepping out from UPM's shadow. Where to? They're headed for the big league, getting listed on Nasdaq Helsinki....

Continue Reading
XPeng Hits New Monthly Delivery Record in October

Updated Category News Views 247

XPeng Smashes Delivery Records Yet Again Ah, the green light’s on for XPeng, and it's a bright one! This October, we learned that XPeng hit the throttle hard with a new record of 50,237 vehicles delivered. Now, that's a sizable rally—a 22% climb month-over-month and shooting 20% higher than last October. For a company like XPeng, which resembles a bulldog with its...

Continue Reading
Smart Salary Moves for S Corp Owners: Riggs Unpacks Insights

Updated Category News Views 197

Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...

Continue Reading

Top 5 Most Recently Viewed Articles

The Growing Impact of Generative AI in Data Labeling Services

Updated Category News Views 204

Transforming Data Labeling with Generative AI In an era where technology continues to redefine business strategies, the Generative AI in Data Labeling Solutions and Services market is emerging as a powerhouse. This sector is experiencing a remarkable trajectory, with projections indicating a potential revenue surge to USD 15.5 billion by the end of 2024, and an impressive...

Continue Reading
argenx to Host Mid-Year Financial Call and Business Update

Updated Category News Views 161

Overview of the Upcoming Financial Results argenx is set to outline its financial accomplishments from the first half of 2025 alongside a strategic business update during a scheduled conference call on July 31, 2025. The call is intended to provide investors and stakeholders with insights into the company’s operational progress and financial metrics. Event Details The...

Continue Reading
Can Exclzyme Pet Revolutionize Joint Health for Dogs?

Updated Category News Views 19

Exclzyme Pet™: A Game-Changer in Pet Health Hot off the press, Chino, California brings us a delightful bit of science that’s got more than a few tails wagging. Specialty Enzymes & Probiotics claim their Exclzyme Pet™ product is something of a magic bullet for joint health in dogs. This isn’t just another chewable trying to woo pet owners with sparkly marketing...

Continue Reading
Strengthening Connections: 4iG Group and Elisa Polystar Unite

Updated Category News Views 216

4iG Group and Elisa Polystar Forge Stronger Partnership The collaboration between 4iG Group and Elisa Polystar marks a significant enhancement in network service performance, aiming to elevate customer experiences through cutting-edge technology. Implementing an AI-Enabled Network System As part of this strategic partnership, an innovative network service monitoring...

Continue Reading
Mizuho's Positive Outlook on Evergy: Valuation and Growth Potential

Updated Category News Views 166

Mizuho Starts Coverage on Evergy with Positive Outlook Recently, Mizuho initiated coverage on Evergy (NASDAQ: EVRG), a prominent utility company, awarding it an Outperform rating coupled with a price target set at $67.00. The firm’s insights reveal that Evergy is currently trading at an approximately 12% discount in terms of price-to-earnings (P/E) compared to its...

Continue Reading